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Human induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) have
applications in diseasemodeling, cell therapy, drug screening and personalizedmedicine.
Computational models can be used to interpret experimental findings in iPSC-CMs,
provide mechanistic insights, and translate these findings to adult cardiomyocyte
(CM) electrophysiology. However, different cell lines display different expression of ion
channels, pumps and receptors, and show differences in electrophysiology. In this
exploratory study, we use a mathematical model based on iPSC-CMs from Cellular
Dynamic International (CDI, iCell), and compare its predictions to novel experimental
recordings made with the Axiogenesis Cor.4U line. We show that tailoring this model
to the specific cell line, even using limited data and a relatively simple approach, leads to
improved predictions of baseline behavior and response to drugs. This demonstrates the
need and the feasibility to tailor models to individual cell lines, although a more refined
approach will be needed to characterize individual currents, address differences in ion
current kinetics, and further improve these results.
Keywords: cardiomyocytes, stem cell derived, electrophysiology, mathematical model, pharmacology, variability,
computational model
1. INTRODUCTION
Induced pluripotent stem cells (iPSCs) can be generated by harvesting fully differentiated and
mature somatic cells from donors and reprogramming them to the pluripotent state (Takahashi
et al., 2007; Yu et al., 2007). From this state, similarly to embryonic stem cells (ESCs), iPSCs can
be differentiated into cell types used for drug screening, disease modeling, cell therapy, and testing
of personalized treatments (Robinton and Daley, 2012; Shi et al., 2017). But unlike ESCs, iPSCs
are harvested from mature donors, which greatly increases their availability, can provide patient-
specific cells, and avoids ethical issues associated with the use of embryonic cells (Holm, 2008).
Compared to animal ex-vivo cell models, iPSCs avoid issues of inter-species differences in protein
expression and cellular physiology (Houser et al., 2012; Milani-Nejad and Janssen, 2014).
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Differentiation of iPSCs into cardiomyocytes (CMs)
is a relatively well-established methodology (Lian et al.,
2013), allowing iPSC-derived CMs to be used in many
different applications. These iPSC-CMs share some important
characteristics with adult CMs: In terms of gene expression,
iPSC-CMs show a pattern that is consistent with adult CMs
(Kattman et al., 2011; Burridge et al., 2014; Bedada et al., 2016).
Functionally, iPSC-CMs display most major types of ion current
seen in adult CMs, including the fast inward sodium current
(INa), the transient outward potassium current (Ito), the L-
and T-type calcium currents (ICaL and ICaT), the rapid and
slowly activating delayed rectifier potassium currents (IKr and
IKs), and the hyperpolarization-activated pacemaker current
(If) (Ma et al., 2011; Liang et al., 2013; Knollmann, 2013). In
addition, iPSC-CMs can be created with genetic mutations
that are presented in inherited cardiovascular diseases such as
long QT syndrome (Moretti et al., 2010; Itzhaki et al., 2011;
Yazawa et al., 2011; Egashira et al., 2012; Terrenoire et al., 2013),
catecholaminergic polymorphic ventricular tachycardia (Fatima
et al., 2011; Itzhaki et al., 2012; Jung et al., 2012; Kujala et al.,
2012), and arrhythmogenic right ventricular cardiomyopathy
(Ma et al., 2013). Using iPSC-CMs to investigate these mutations
can provide crucial insights into cellular arrhythmia mechanisms
and the genotype-phenotype correlation of cardiovascular
diseases.
In drug screening and discovery, iPSC-CMs can be used to
evaluate proarrhythmic risk. Here, iPSC-CMs can be used as
in vitro models that closely resemble human physiology and
patient-specific conditions (Ebert et al., 2012; Mathur et al., 2015;
Avior et al., 2016). Recently, such in vitro studies have become
more important for drug evaluation (Friedrichs et al., 2005;
Pugsley, 2005; Lindgren et al., 2008; Giorgi et al., 2010) and the
use of iPSC-CMs in drug safety pipelines has been proposed by
the Food and Drug Administration (FDA)-led “Comprehensive
in vitro Proarrhythmia Assay” (CiPA) initiative (Sager et al.,
2014; Ando et al., 2017). As part of CiPA it is intended that
iPSC-CMs act as a check on mathematical model predictions of
pro-arrhythmic risk.
However, some care needs to be taken when interpreting
the results of experiments on iPSC-CMs, as many differences
between iPSC-CMs and adult CMs still exist. For example, iPSC-
CMs have a smaller average cell size (Polak and Fijorek, 2012),
lack T-tubules (Lieu et al., 2009) and have lower contractile force
(Rodriguez et al., 2014). Their calcium handling machinery is
underdeveloped, including changes to calcium-induced calcium
release, buffering in the sarcoplasmic reticulum and recycling
of calcium by SERCA (Sedan and Binah, 2011; Blazeski et al.,
2012), although this is still under debate (Hwang et al.,
2015). The expression levels of some ion channel genes also
show some important differences. Unlike adult CMs, iPSC-
CMs have little IK1 current (van den Heuvel et al., 2014),
and a prominent If current (Knollmann, 2013; Keung et al.,
2014). These different current characteristics of iPSC-CMs
give rise to a relatively positive diastolic potential and slower
upstroke velocity compared with adult CMs. The need to further
understand these sub-cellular differences, to translate findings
in iPSC-CMs to adult myocytes, and to understand how they
relate to cell and tissue-level effects, has driven researchers to
develop computational models of iPSC-CMs (Paci et al., 2013,
2015).
Each iPSC-CM cell line is developed from a donor with a
particular genetic background, using a specific set of protocols
from differentiation to maturation. Besides the differences in
iPSC-CM and adult-CM electrophysiology, differences between
iPSC-CM cell lines have also been shown (Okano et al., 2013;
Priori et al., 2013; Moran et al., 2014; Du et al., 2015). Cell-to-
cell variability of ion current characteristics within a single line
of iPSC-CMs was also observed (López-Redondo et al., 2016)
which, as in adult CMs, can have strong implications for our
understanding of cell electrophysiology and prediction of drug
effects (Mirams et al., 2016).
To use and trust iPSC-CMs as an in vitro model for drug
screening and disease modeling, it is crucial to evaluate
the differences between cell lines and the intra-cell line
variability, and to understand how these differences impact
experimental outcomes (Karakikes et al., 2015; Del Álamo
et al., 2016). Computational modeling can be used to
understand and to quantify this intra- and inter-cell line
variability, and to gain mechanistic insights into iPSC-CM
electrophysiology.
But how detailed does such modeling work need to be? Can a
model based on one cell line be used to make inferences about
another? How much, and what type of experimental data is
needed to tailor a model to a new cell type, or even an individual
cell?
In this exploratory study, we compared electrophysiological
characteristics of the Cor.4U iPSC-CM cell line (Axiogenesis
AG, Germany) to a model by Paci et al. (2013), based
on the Ma et al. (2011) studies of an iPSC-CM cell line
from Cellular Dynamics International (CDI), iCell. First, we
measured the maximum conductances of sodium, calcium
and lumped outward currents in individual Cor.4U cells,
and by comparing this to model predictions we attempted
to infer the maximum conductances of the individual ionic
currents. We focused on the maximum conductances of INa,
ICaL, IKs, INaCa. These maximum conductances were then
used to tailor the Paci et al. (2013) model to create cell-
specific models of 22 different Cor.4U cells. Using these
tailored models to simulate APs, we found a variety of AP
waveforms exhibiting a high level of variability similar to that
found in real iPSC-CMs. We then optically measured action
potential durations (APDs) in iPSC-CM cultures under both
control and drug-applied conditions, and found that—in most
cases—tailored models predicted the resulting changes better
than the original model. This suggests that the ion current
composition differs between cell lines, and highlights the need
to tailor in silico models to different cell lines to interpret
drug-induced alterations to their electrophysiology. Our results
also show that even a relatively simple approach, in which
only the maximum conductances are considered with limited
experimental data, can already provide useful information in
this regard, but that more intricate methods will be needed to
characterize differences in outward currents between iPSC-CM
cell lines.
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2. METHODS
2.1. Current Measurements in Cor.4U Cells
Sodium, calcium, and lumped outward currents were measured
in Cor.4U cells in the whole-cell patch clamp configuration
using theNanion SyncroPatch 96 platform (Nanion Technologies
GmbH, Germany). Sodium and lumped outward currents were
measured using an intracellular solution containing (in mM)
50 KCl, 60 KF, 10 NaCl, 10 HEPES, and 20 EGTA (pH: 7.2),
and a bath solution containing (in mM) 150 NaCl, 4 KCl, 1
MgCl2, 1.2 CaCl2, 10 HEPES, and 5 glucose (pH: 7.4). Calcium
current recordings were made using an intracellular solution
containing (in mM) 50 CsCl, 60 CsF, 10 TEA-Cl (a potassium
current blocker), 5 HEPES, 10 EGTA, 4 Na2-ATP, 0.1 Na-GTP,
and 0.1 cAMP (pH: 7.2) and a bath solution containing (in mM)
130 NMDG, 10 BaCl2, 4 CsCl2, 1 MgCl2, 2 CaCl2, 10 HEPES,
and 5 glucose (pH: 7.4). All currents were recorded at room
temperature.
For the sodium current measurements, cells were held at
−80mV and then stepped to potentials ranging from −60 to
60mV with 10mV increments, before returning to the holding
potential. The step duration was 20ms and the interval between
steps was 5 s. The calcium current experiments used a similar
protocol, but with 200ms steps from −40 to 40mV. Outward
current was measured with 500ms steps from−40 to 50mV, with
a 10 s interval between steps. All three protocols are shown in
Supplementary Figure S1.
For the outward current experiments, we fitted directly to
the experimental current traces (see section 2.5), and so leak
correction was applied using Ileak = V/Rleak where Rleak was the
leak resistance estimated at the holding potential. Capacitance
artifacts were filtered out by omitting the first 10ms after each
change in potential (see e.g., Ogden and Stanfield, 1994).
2.2. Patch Clamp AP Measurements in
iPSC-CMs
Action potentials in iCell iPSC-CMs (CDI, USA) plated
on coverslips were measured in whole-cell patch clamp
configuration using a HEKA amplifier (EPC 10 USB Triple,
HEKA Elektronik, Germany). Recordings were made using a
pipette solution containing (in mM) 10 NaCl, 125 KCl, 1 MgCl2,
10 HEPES, 0.1 Na3GTP, 5 Mg-ATP, 5 EGTA (pH 7.2) and a
bath solution containing (in mM) 150 NaCl, 4 KCl, 1.2 CaCl2, 1
MgCl2, 10 HEPES (pH 7.4). Cells were stimulated at a frequency
of 1.0Hz, for at least 50 cycles before recording.
2.3. Optical Mapping AP Measurements in
Cor.4U Cultures
Action potentials were recorded from Cor.4U cultures with
optical mapping using the CellOPTIQ electrophysiology
platform (Clyde Biosciences Ltd). Cells were incubated in serum-
free media at 35 ± 2◦C, and transiently loaded with voltage
sensitive fluorescent dye di-4-ANEPPS (20µL of stock solution
27mM in ethanol; University of Connecticut Health Center). The
loaded dye was then excited with a peak wavelength 470 nm LED,
and the emitted fluorescence from the Cor.4U iPSC-CMs was
recorded at a sample frequency of 10 kHz. Measurements were
performed before and after addition of Dofetilide, Quinidine,
Sotalol and Verapamil at the concentrations shown in Table 1.
Paracetamol was applied as a negative control.
A semi-automatic data analysis method based in Wang et al.
(2015) was employed to normalize the data. In short, heuristics
were used to form an initial estimate of the start and end time
of the AP. The region just before the estimated upstroke was
used to determine Vnormalized= 0, while the 95th percentile of the
data during the (estimated) AP was used as Vnormalized= 1. We
then calculated the final APD90 and APD50 from this normalized
signal.
2.4. Simulated Experiments
Simulations of the patch clamp protocols were carried out
using the model by Paci et al. (2013). Initial intracellular and
extracellular ion concentrations were set to the values used in
the experiments. For the INa, ICaL, and Ioutward voltage clamp
experiments, concentrations were clamped (corresponding to
the buffering effects of the pipette), but for AP simulations
concentrations were allowed to vary following model equations.
The temperature parameter in the model, which affects reversal
potentials as well as ICaL permeability and IKr, INaK, and INaCa
kinetics, was set to 25◦C (298K) to match the experimental
temperature. Simulations were run using Myokit (Clerx et al.,
2016), with CVODE (Hindmarsh et al., 2005) set to the
default tolerance settings of abs_tol= 10−6 and rel_tol= 10−4.
Model code was imported from a CellML (Cuellar et al.,
2003) file downloaded from the Physiome model repository
(Yu et al., 2011). Numerical integration was carried out using
NumPy/SciPy (Jones et al., 2001). All codes and data are
freely available from https://gitlab.com/MichaelClerx/tailored-
ipsc-models.
2.5. Estimating Maximum Conductances of
Individual Ion Currents
The maximum conductance of INa was estimated by scaling the
INa conductance in the Paci model to match the peak current
recorded experimentally with the sodium protocol (n= 35 cells),
based on the assumption that the peak current is composed of
INa alone. We tested this assumption by running a simulated
experiment, where we observed that INa alone would reach 1.01×
the initial inward deflection after each voltage step. So the peak is
almost entirely due to sodium and only decreased slightly by the
presence of other currents. Similarly, the recordings made with
the calcium protocol (n= 25 cells) were used to directly infer the
maximum conductance of ICaL.
To estimate the conductances of the remaining major
currents, we used the recordings made with the outward-current
protocol (n = 22 cells). Using the iPSC model by Paci et al.
(2013) we simulated the response to this protocol of INa, ICaL,
IK1, IKr, IKs, Ito, If, and INaCa (see Supplementary Figure S2).
We then tried to find a weighted sum of these simulated
currents that could replicate the measured signal. This was done
by minimizing the sum of square errors between measured
and simulated current during the voltage steps, using the
optimization method CMA-ES (Hansen, 2006). The procedure
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TABLE 1 | Summary of the applied reference drugs which are a variety of multi-channel blockers, including the IC50 values for the corresponding ion channels, and the
applied drug concentration (x).
IC50 [µM] Dofetilide Quinidine Sotalol Verapamil
IKr 0.0052
a 0.3b 111.4d 0.25d
INa 147.9
a 16.6c 7013.9d 32.5d
ICaL 26.7
a 15.6c 193.3d 0.2d
IKs 415.8
a No significant effect No significant effect No significant effect
x [µM] 0.03, 0.1, 0.3, 1.0 0.01, 0.1, 1.0, 10 0.3, 3.0, 30, 300 0.01, 0.1, 1.0, 10
The IC50 data are from a, Obejero-Paz et al. (2015); b, Po et al. (1999); c, Mirams et al. (2011); and d, Kramer et al. (2013).
was repeated for each of the 22 measured cells, resulting in a
unique set of scaling factors per cell.
While this protocol was intended to find values for only
the outward currents (such as IKr, IKs, and Ito) we chose to
vary the inward currents INa and ICaL in the optimization to
reduce the risk that any inward currents in the signal would
erroneously be attributed to the outward currents (see e.g., Sarkar
and Sobie, 2010). Note that we do not use these fitted INa and
ICaL conductances because we fit these from other dedicated
experiments; they were included here just to yield more accurate
outward current fits. After finding that the most prominent
outward currents were IKs and INaCa (see section 3.2), we ran a
second optimization with only IKs and INaCa: little change was
observed, but we expect that fitting outward currents together
with INa and ICaL is likely to yield slightly more accurate results.
Convergence of the optimization results was verified by
repeating the process 10 times, using different random seeds
for each run. We found that the L2 norm of the difference
between the first and repeated scaling factor vectors was smaller
than 10−5 for all 10 random starting points. To further verify
the identifiability of the problem, we performed the same
analysis on synthetic data (with synthetic noise), and were
able to successfully infer the conductance scaling factors (see
Supplementary Figure S4 and Supplementary Table S1). We note
that this analysis assumes the kinetics of the currents have low
model discrepancy, i.e., reflect the kinetics of the real currents
well.
Finally, to quantify the contribution of each current to the






where Ifinal,i was defined as the current measured at the end of the
final step of the outward-current protocol. This measure simply
gives us a sense of the proportion of outward current that is
contributed by each individual component during the end of the
50mV step, but it is not used in tailoring the models.
2.6. Predicting the Shape of the AP
Next, the estimated maximum conductances were used to tailor
the Paci et al. (2013) model to individual cells from the Cor.4U
cell line. A total of 22 model variants were parameterized,
corresponding to the 22 cells for which the outward current was
measured. Since we found many currents were not discernible in
the recorded outward current (see Table 2), we only applied the
cell-specific scaling factors for IKs and INaCa. All tailored models
used the same INa and ICaL scaling factors, found in the inward
current experiments which were measured in different cells and
hence any covariance could not be accounted for. The remaining
currents were left unchanged, as they are necessary for other
cellular behavior, such as homeostasis, even though they might
not contribute strongly to the recorded outward current. Note
that we have used only linear scaling of the conductances, and the
current kinetics of the original currents were not altered. Finally,
Na+, K+, and Ca2+ evolve in time according to the Paci et al.
(2013) model, to mimic the intact cell conditions of our optical
mapping experiments.
These tailored models were then used to simulate baseline
APs, as well as APs with drug perturbation. The effects of drugs
on ion current maximum conductances were modeled using the





where x denotes the concentration of the applied drug, IC50 is
the inhibitory concentration 50% value, h is the Hill coefficient,
and f (x) is a scaling factor for the maximum conductance that
varies from 0 (full block) to 1 (no block).
For each cell and each drug, a model was created where
the maximum conductances of the ion currents were scaled
according to Equation (2) using the IC50 values from Table 1
and a Hill coefficient of 1.0. For comparison, the same scaling
factors were applied to an original model with the untailored
conductance values from Paci et al. (2013).
In our optical mapping experiments, cells formed a
spontaneously-beating and electrotonically-coupled monolayer.
However, in this preparation not all cells beat at their
spontaneous rates. Most cells will fire an AP when triggered
by an activation wave from their neighbors rather than
spontaneously, and a relatively small region of (by definition)
faster spontaneously-beating cells sets the pacing rate for the
entire monolayer. Therefore, to mimic this effect, we paced
the cells at the mean rates observed in the optical mapping
experiments, for a given compound, to account for any AP rate
dependency. We used the cycle lengths of 1.375 s for Dofetilide,
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TABLE 2 | The scaling factors (s) and the relative contribution (c) of individual ion currents to the measured outward current in Cor.4U cells (n = 22).
Cell INaCa IKs IKr IK1 If
s c s c s c s c s c
1 3.32 28.5 139 71.2 — — — — — —
2 2.08 21.2 129 78.5 — — — — — —
3 7.55 50.3 125 49.5 — — — — — —
4 21.1 43 467 56.8 — — — — — —
5 6.89 29.9 270 70 — — — — 1.18 —
6 9.3 42.4 211 57.4 — — — — — —
7 0.951 29.6 37.6 69.9 — — — — — —
8 1.54 56.7 19.5 42.8 — — 0.118 0.000258 — —
9 1.7 35.2 52 64.3 — — — — — —
10 1.67 98.6 — — — — 0.104 0.000362 — —
11 0.38 16.7 31.5 82.5 — — — — — —
12 0.696 38.2 18.6 60.9 — — — — — —
13 3.05 25 153 74.7 — — — — — —
14 1.28 14.7 125 84.9 — — — — — —
15 1.19 34.1 38.3 65.3 — — — — — —
16 3.02 51.4 47.3 48 — — — — — —
17 2.35 59 27 40.4 — — — — — —
18 4.03 32.7 138 66.9 — — — — — —
19 5.74 73.4 28.9 22 1.84 4.5 0.513 0.000388 — —
20 2.35 80.5 9.18 18.8 — — 1.18 0.0024 — —
21 3.77 40.2 93.7 59.6 — — — — — —
22 13.9 44.6 288 55.1 — — — — — —
Values lower than 10−10 are shown as dashes (—). The scaling factors are taken with respect to the maximum conductance found in the original Paci et al. (2013) model. Ito values
were lower than 10−10 for all cells. Because of the many low values for Ito, IKr, IK1, and If, only the values for INaCa and IKs were used to create the tailored models.
1.176 s for Quinidine, 0.933 s for Sotalol, 0.905 s for Verapamil
and 1.0 s for Paracetamol and all other experiments. To allow
direct comparison with the optical mapping data, the simulated
AP was normalized using the same algorithm (see section 2.3).
3. RESULTS
3.1. INa and ICaL in Cor.4U Cells
Figure 1 shows the peak current-voltage relationships for INa
and ICaL, measured in Cor.4U cells. The mean peak current
in 35 cells (INa) and 25 cells (ICaL) is plotted, as are the 25th
and 75th percentiles. Compared to the prediction of the original
Paci et al. (2013) model (created from iCell iPSC-CM data),
the experimental data show a lower amplitude of both currents
in Cor.4U cells. We had to scale by a factor 0.69 to match
the mean peak INa, and 0.80 to match the mean peak ICaL
recordings. The simulated INa peaked at the same potential as
the experimental data, suggesting the activation kinetics of INa in
iCell and Cor.4U cell lines are similar. The simulated ICaL kinetics
followed the Paci et al. (2013) model, and were left-shifted
relative to experimental data. Further experiments established
that this shift was due to a right-shift in the experimental IV
curve due to Ba2+ being present in the ICaL voltage clamp
experiment bath solution (see Supplementary Figure S3), hence
we do not adjust the kinetic terms and tailor only the maximum
conductance.
3.2. The Outward Protocol Strongly Elicits
IKs
Figure 2 (left panel) shows the current measured with the
outward-current protocol in a single Cor.4U cell. To analyse the
composition of this current, we simulated the same protocol, and
looked for a sum of scaled transmembrane currents from the Paci
et al. (2013) model that gave a similar result (see section 2.5).
We repeated this process for each of the 22 cells with measured
outward current, and obtained the scaling factors s for each cell
and current shown in Table 2. Note that the scaling factors s are
relative to the original Paci et al. (2013) model. In many cases, the
optimization routine indicated that the kinetic profile of certain
currents was not discernible in the measured outward current.
This is indicated in the table with a dash (—) for any scaling factor
smaller than 10 -10. After seeing these results, as a comparison,
we also tried fitting by varying only IKs and INaCa (and using the
scaling factors for INa and ICaL determined previously), and the
results are similar (see Supplementary Table S2).
For most cells, we found that the measured responses differed
greatly, in both the shape and size of the currents, from
the original model predictions (see Supplementary Figure S4),
leading to a poor quality of fit (see Supplementary Figure S5).
As a result, the best reconstructions of the simulated current
relied almost entirely on a greatly amplified IKs current, along
with strong INaCa, while other currents such as IKr and If were
notably absent. Based on this, we might assume that IKs and
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FIGURE 1 | Current-voltage relationship for INa (left) and ICaL (right). The red lines represent the mean peak current measured experimentally in 35 (INa) and 25 cells
(ICaL), and the shaded areas show the 25th and 75th percentiles of the experimental data. The peak-current voltage relation simulated with the unaltered Paci et al.
(2013) model for the same protocol is shown in blue. The orange lines show the simulated results after scaling to match the maximum current.
FIGURE 2 | Left: Experimentally measured outward current in cell 19 during the outward protocol. Data to the left of the vertical red was omitted to remove
capacitance artifacts. Right: Simulated transmembrane current during the same protocol, as set during the optimization process for cell 19. Note that this figure
includes all scaling factors set by the optimization routine (see section 2.5), including ones not included in the final tailored models (such as INa and IKr). More
examples of fits are shown in Supplementary Figure S5.
INaCa are more strongly expressed in Cor.4U cells than in the
iCell cells the Paci et al. (2013) model was based on. As an initial
verification of these findings, we repeated some outward current
measurements in the presence of Chromanol (an IKs blocker),
see Supplementary Figure S6 for an example where IKs is indeed
significant. The near-zero contributions of other currents (e.g.,
IKr) does not imply that these currents are completely absent in
Cor.4U cells, but instead suggests that the currents as simulated
from the model could not be found in our recordings using the
specified patch clamp protocol. This is a strong hint that changes
to the kinetics of the currents will be required to accurately
simulate the ion currents in Cor.4U cells at this temperature
using the model by Paci et al. (2013). Such a mismatch in
kinetics would also explain the large remaining errors between
measurements and fit seen in Supplementary Figure S5, causing
other currents, such as IKr, to be fitted as absent. This is discussed
further in section 4.4.
3.3. Tailored Models
We then created tailored models by modifying the original Paci
et al. (2013) model in two ways: First, we scaled the maximum
conductances of INa and ICaL by a factor 0.69 and 0.8 respectively,
to match the averaged data from the inward current experiments.
We then further modified this model to create 22 tailored models
based on the 22 cells in which outward current was measured, by
applying the IKs and INaCa scaling factors from Table 2.
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3.4. Variability in Ioutward Predicts Variability
in AP
Significant variability in the outward currents was observed
among the Cor.4U cells. This can be seen from the scaling
factors in Table 2, but it is also evident when directly inspecting
the currents measured from different cells (see Supplementary
Figure S5) or when looking at peak Ioutward (see Supplementary
Figure S7).
Figure 3 (left panel) shows APs simulated with the tailored
models. A wide variety of APs could be seen, with some
models showing a spike-and-dome waveform, some showing a
more triangular waveform, and with a varying slope in resting
potential (leading to different degrees of auto-excitation). Some
models also show beat-to-beat alternans, or fail to completely
depolarize. The corresponding contribution of themajor currents
throughout the APs are also shown in Supplementary Figure S8.
Recordings of APs in single iPSC-CMs show a similar variety
of AP waveforms. Figure 2 (right panel) shows APs measured
in 7 different iCell iPSC-CMs. Again, various waveform
morphologies (roughly corresponding to atrial, ventricular and
sinoatrial node APs) and differing levels of auto-excitability can
be distinguished. Whilst these recordings are for a different cell
line than our tailored models, the inter-cell variability in channel
expression within a batch of iPSC-CMs has not been observed to
be markedly different between cell lines (see e.g., the relative size
of the “error bars” in Figure 2 of Blinova et al., 2017).
3.5. Tailored Models Improve Predictions of
APD
Figure 4 (left panel) shows the median of all simulated traces as
shown in Figure 3, along with the 25th and 75th percentiles. The
optically recorded APs from the Cor.4U cells were plotted on the
same graph (the median shown as black line and the 25th and
75th percentiles shown as gray shading). Due to the increased
outward current, the tailored models exhibit a shorter APD
than the original model, that matches the measured APDs more
closely in the early and late repolarization phase. A histogram
of APDs in measured and simulated cells is shown in Figure 4
(right panel), with the blue line representing the result from
the original model. A similar histogram for APD50 is shown in
Supplementary Figure S9.
3.6. Tailored Models Can Give Better
Prediction of Drug Block Effects
Figure 5 shows the dose-response curves of the APD90 of four
drugs, measured experimentally and simulated using the original
and tailored models. Equivalent results using the of the APD50
are shown in Supplementary Figure S9. Results for the control
drug paracetamol are shown in Supplementary Figure S10. For
all four drugs tested, although not fitting the experimental data
exactly, the tailored models match the measured data more
closely than the original model. For Dofetilide in particular,
the tailored models show a realistically smaller increase in
APD than the original model, which shows alternans and
then repolarization failure at higher drug concentrations. For
Quinidine, although the tailored models do not fit better at
the highest concentration, we improve the predictions at lower
concentrations.
Predictions made with the adult-CM model by O’Hara et al.
(2011) are shown for comparison. Note how the adult CMmodel
predicts APD prolongation with Verapamil, whereas both the
tailored and original iPSC-CM models accurately predict the
shortening that is observed in iPSC-CM optical mapping. Such
qualitative differences highlight the need for models specific to
iPSC-CMs to interpret experimental findings in these cells.
4. DISCUSSION
Pre-clinical studies with iPSC-CMs can be used to evaluate
proarrhythmic risk of compounds at the early drug discovery
and development phase for compound optimization, and these
experimental results can directly contribute to the design of safe
FIGURE 3 | Predicted variability in the tailored action potential models is similar to inter-cell variability in a batch of iPSC-CMs. Left: Simulated APs from the 22 tailored
cell-specific Cor.4U models exhibit a variety of AP waveforms. Right: Experimentally measured APs in seven individual iCell iPSC-CMs also show significant variability.
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FIGURE 4 | Left: The predicted 1Hz steady pacing APs from the individual cell optimized models (orange), the original Paci model (dashed blue), and optical
mapping measurements (black) in the control conditions. We show the median and 25th and 75th percentiles of the optical mapping (gray) and action potential
models (orange). All data shown are normalized (see section 2.3). For models that exhibited strong alternans (i.e., where only every second AP showed a
spike-and-dome morphology) the longer of the two APs was used. Right: A histogram of APD90 in the fitted models and optical mapping control (drug free)
experiments. As we might expect, there is more variation in APD in the individual-cell tailored action potential models than the electrotonically-coupled tissue
measurements, but the distribution is centred appropriately.
first-in-human doses. Ideally, for reliable risk identification and
translation, the electrophysiology of iPSC-CMs should accurately
reflect that of adult cardiomyocytes. Yet the characteristics of
iPSC-CMs are influenced by donor genetic background as well
as differentiation and maturation protocols, and so differences
between iPSC-CM cell lines may be expected, as well as
differences from adult CMs. Mathematical models of the cellular
AP can be used to gain mechanistic insight into such differences
and to build a quantitative translational framework between
iPSC-CMs and human adult CMs.
In this study we compared novel measurements in Cor.4U
iPSC-CMs with predictions from a model based on the iCell
cells. We found a decrease in INa and ICaL current densities,
but a large increase in IKs and more modest increases in INaCa.
Using the simple method of scaling maximum conductances—
without altering ion current kinetics—we created models tailored
to individual iPSC-CMs. The obtained fits were not optimal,
which suggests that the ion current kinetics in the iCell-
cell based model by Paci et al. (2013) do not closely match
those in Cor.4U cells. However, like real iPSC-CMs, these
tailored models show differences in AP from cell to cell,
with AP waveforms broadly similar to ventricular, atrial and
sinoatrial-node APs. The predicted single-cell APD90 was
shorter in tailored models than in the original model, and
showed a better match with optical mapping measurements
in electrotonically-coupled iPSC-CM cultures. The effects of
Dofetilide, Quinidine, Sotalol and Verapamil on APD were
simulated, and again the tailored models provided a closer fit.
These results show that there are important electrophysiological
differences between iPSC-CM cell lines, but that relatively simple
adjustments to computational iPSC-CM models can already
partially accommodate them. This has important implications
for the suggested drug-screening workflows: one should really
combine both iPSC-CM measurements and computational
modeling of iPSC-CM for better interpretation of the iPSC-CM
data in terms of its variability and translational power.
4.1. Cell-Line Differences in Ion Current
Densities
We obtained maximum conductance values for the inward
currents INa and ICaL that are lower than suggested by the
Paci et al. (2013) model based on iCell cells, while IKs
and INaCa were increased in most Cor.4U cells. The slight
reduction in ICaL and increase in IKs suggests a decrease
in APD. This was borne out by the AP simulations, and
was consistent with our optical mapping measurements which
showed shorter APDs compared to the AP simulated by
the original Paci model. Our simulations displayed a similar
degree of AP variability to the experimental iPSC recordings,
but larger variability than the optical mapping measurements.
Both findings are consistent given that electrotonic coupling
of cells (present in the optical mapping experiments) reduces
variability.
A potential explanation of the large IKs current is suggested
by Lei et al. (2017). It shows that both the KCNQ1 and
KCNE1 (subunits of the channel carrying IKs) were present in
our Cor.4U cells, however, KCNE1 was not as well expressed
in iCells. The difference in KCNE1 expression could lead to
the observed larger IKs currents in the Cor.4U cells compared
to iCells, and hence a shorter APD and less prolongation
under IKr blockers, which is in agreement with Blinova et al.
(2017). Our observation is supported by Silva and Rudy
(2005) who found that native IKs (from channels comprised of
both KCNQ1 and KCNE1) activates more than with KCNQ1
only.
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FIGURE 5 | Dose-response curves of the APD90 for four drugs: Dofetilide, Quinidine, Sotalol, and Verapamil. The individual optical mapping measurements are
shown as black dots, with the median shown as a dotted black line. Predicted responses from the original model are shown in blue, and the tailored model predictions
are shown in orange (solid line is median and shaded region indicates 25th–75th percentiles. Models (tailored or original) that exhibited strong alternans (i.e., where
only every second AP showed a spike-and-dome morphology) were omitted from the figure. Because this caused the number of predictions in the tailored model
distribution to vary, the minimum and maximum number of predictions per drug is shown as n = minimum − maximum. At higher concentrations, Dofetilide block
causes repolarization failure in both the original model and the O’Hara model.
4.2. Cell-to-Cell Differences in iPSC-CMs
iPSC cardiomyocytes, from the same donor and
differentiated/matured in the same way, can display vastly
different AP waveforms, reminiscent of those of ventricular,
atrial, and sinoatrial-node cells. Our tailored models, created
by varying the maximum conductances of INaCa and IKs,
showed a similar model-to-model (cell-to-cell) variety in style of
generated APs. This shows that variation in genetic expression,
which correlates directly with maximum conductance (Schulz
et al., 2006), could be enough to explain the different AP
waveforms observed in iPSC-CMs. However, it does not
preclude other explanations, and it is possible the APs could
take on a more distinct shape if differences in ion channel
kinetics were also included. As discussed in a recent white
paper, the inclusion of cell-cell variability, as well as variability
between cell lines is an important research area (Johnstone et al.,
2016).
4.3. Predictions of Drug Action
The sharp increase in IKs seen in our Cor.4U tailored models
suggests Cor.4U cells have a stronger reliance on IKs as a
repolarizing force, and will therefore be less likely to show AP
prolongation when treated with IKr blocking drugs (see, e.g., the
Figure 5 of Blinova et al., 2017, which shows, for 8 out of 12 drugs
with comparable concentrations and prolongation in iCells, the
Cor.4U cells have a smaller APD prolongation than the iCells).
Consistent with this suggestion, simulations of treatment with
the potent IKr blocker Dofetilide showed only a modest increase
in APD at concentrations that caused the iCell-cell based model
to display excessive AP prolongation resulting in alternans.
Treatment with Quinidine, a less potent IKr blocker, showed
similar results. The modest APD increase predicted by the
tailored models underestimated the APD prolongation observed
in the data, suggesting the role of IKr as a repolarizing force was
underestimated in these models. More refined experiments will
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need to be conducted to separate the outward currents and to
better estimate IKr conductance. Application of Verapamil, which
blocks ICaL as well as IKr, had a smaller effect in our tailored
models than in the original model, which is consistent with the
lowered levels of IKr and ICaL.
The strong IKs-reliance we observedmay be problematic when
using these iPSC-CMs as models for ventricular myocytes, where
IKs only plays a major part when other repolarizing currents are
blocked or in the presence of sympathetic stimulation (Jost et al.,
2005).
4.4. Limitations and Future Work
This study showed the need to build cell-line or even cell-
specific models for iPSC-CMs, and this work serves as a pilot
attempt for such an approach. However, a refined study with
additional experiments will be needed to improve the tailored
models further.
As might be expected, the ion current profiles during voltage
steps could not be recreated well using this approach. It is likely
that ion channel kinetics also vary between cell lines due to (e.g.,)
differences in subunit expression (Lei et al., 2017), although this
could also be partly due to the difference of temperature, and that
the model we used does not accurately capture the kinetics of
ion currents in Cor.4U cells. Channel kinetics play an important
role in the contribution of a current to the different phases of
the AP. Modifying the kinetic parameters which characterize
the voltage-current relationship for the activation, inactivation,
deactivation, etc. of a channel could change both the current
and the AP, and would influence responses to drugs. Varying
the kinetic parameters would also alter the conductances we
estimated by fitting the outward current. Further tailoring the
models to include refitted kinetic parameters may lead to further
improvements in predictive power. However, since models of ion
channel kinetics contain many parameters, specifically designed
experiments (e.g., with channel blockers and/or specialized
voltage protocols) will be required to refine these tailored
models.
The method of fitting multiple currents to a single
experimental recording is a highly useful approach, as it reduces
the number of experiments needed to tailor a model. However,
due to the limitation of experiments being performed in
different cells, we were not able to examine the covariance
between the inward and outward currents. Also, since it depends
on the number of current conductances to be fitted and
the experimental data (e.g., the quality of the data and the
actual current shape), one may run into problems of practical
identifiability if one tries to refit kinetic parameters here (e.g.,
multiple combinations of conductance and kinetic parameters
that can provide an equally good fit, as in Fink and Noble,
2009). Additional experimental data with refined experimental
designs will be needed to identify all parameters; for example,
to perform experiments with channel blockers to isolate the
contribution of particular currents, or to iteratively refine the
models using a dynamic clamp approach (Devenyi et al.,
2017).
Variability/noise on drug-ion channel interaction parameters
(IC50s) from different labs or repeats of experiments will also
impact our simulation predictions. A probabilistic uncertainty
quantification framework using the techniques proposed in
Elkins et al. (2013), Johnstone et al. (2017) could be used in future
to address this.
Our Cor.4U-tailored predictions of both baseline AP and drug
responses matched the optical mapping data more closely than
the un-tailored model. However, these optical mapping data were
gathered from cultures of spontaneously beating electrotonically
coupled cells, while our simulations are of paced single iPSC-
CMs. Another avenue for future work would be to combine (a
representative distribution of) tailored cell-specific models into
heterogeneous tissue models (Bowler et al., 2016).
4.5. Implications for Drug Testing
iPSC-CMs have gained significant popularity as an in vitro
model for drug screening and, as one pillar of the CiPA
strategy, are anticipated to become a routine part of the
cardiac safety pipeline. It is therefore critical to understand
how to interpret the iPSC-CM data variability (intra- and inter-
cell line variability) and to translate these data to the adult
human situation. Mathematical models are a promising tool
to integrate data, gain mechanistic insights and perform this
translation.
Our results show that differences between iPSC-CM
cell lines can be analyzed and understood using tailored
computational models. Furthermore, even models based on
relatively simple methods (e.g., scaling maximum conductances)
and a limited set of measurements (two inward current and
one outward current experiments) can lead to improved
predictions of baseline and drug-blocked electrophysiology
parameters.
5. CONCLUSIONS
Using a combination of novel experiments and computational
work, we have shown that Cor.4U cells display different ion
current densities than the previously characterized model, which
is based on iCell data. This included an increased reliance on IKs
for repolarization with an accompanying decreased reliance on
IKr. Incorporating these effects in cell-specific models of iPSC-
CMs correctly predicted that this would lead to a shortening
of the baseline APD and a reduced reaction to IKr-blocking
drugs. These predictions were confirmed in optical mapping
experiments with reference drugs, although further refinements
to these methods are clearly needed. We conclude that tailoring
models to specific cell lines—even with imperfect information—
will be a valuable tool for understanding the electrophysiology
of iPSC-CMs and the actions of ion channel-blocking
drugs.
AUTHOR CONTRIBUTIONS
Conception—KW, DG, GM, LP; design—KW, DG, GM, LP;
data collection—KW, RJ, MH-V, VZ, AA, GS, LP; analysis and
interpretation—CL, KW, MC, RJ, DG, GM, LP; writing and
review—CL, KW, MC, DG, GM, LP.
Frontiers in Physiology | www.frontiersin.org 10 December 2017 | Volume 8 | Article 986
Lei et al. Tailoring Models to iPSC-CM Lines
FUNDING
CL acknowledges support from the Clarendon Scholarship
Fund, the Engineering and Physical Sciences Research Council
(EPSRC) and the Medical Research Council (MRC) (Grant
Number EP/L016044/1). KW was supported by a Roche
Post-doctoral Fellowship. MC and DG acknowledge support
from BBSRC grant BB/P010008/1. This work was supported
by the Wellcome Trust [grant number 101222/Z/13/Z]: GM
gratefully acknowledges support from a Sir Henry Dale
Fellowship jointly funded by the Wellcome Trust and the Royal
Society.
ACKNOWLEDGMENTS
We thank Drs. Adrian Roth, Franz Schuler, Thierry Lavé, and
Thomas Singer (F. Hoffmann-La Roche AG) for their scientific
and managerial support.
SUPPLEMENTARY MATERIAL




Ando, H., Yoshinaga, T., Yamamoto, W., Asakura, K., Uda, T., Taniguchi, T.,
et al. (2017). A new paradigm for drug-induced torsadogenic risk assessment
using human ips cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods
84, 111–127. doi: 10.1016/j.vascn.2016.12.003
Avior, Y., Sagi, I., and Benvenisty, N. (2016). Pluripotent stem cells in disease
modelling and drug discovery. Nat. Rev. Mol. Cell Biol. 17, 170–182.
doi: 10.1038/nrm.2015.27
Bedada, F. B., Wheelwright, M., and Metzger, J. M. (2016). Maturation
status of sarcomere structure and function in human ipsc-derived
cardiac myocytes. Biochim. Biophys. Acta 1863(7 Pt. B), 1829–1838.
doi: 10.1016/j.bbamcr.2015.11.005
Blazeski, A., Zhu, R., Hunter, D. W., Weinberg, S. H., Zambidis, E. T., and Tung,
L. (2012). Cardiomyocytes derived from human induced pluripotent stem cells
as models for normal and diseased cardiac electrophysiology and contractility.
Prog. Biophys. Mol. Biol. 110, 166–177. doi: 10.1016/j.pbiomolbio.2012.07.013
Blinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre,
M. P., et al. (2017). Comprehensive translational assessment of human-induced
pluripotent stem cell derived cardiomyocytes for evaluating drug-induced
arrhythmias. Toxicol. Sci. 155, 234–247. doi: 10.1093/toxsci/kfw200
Bowler, L., Harris, K., Gavaghan, D., and Mirams, G. (2016). Simulated
micro-electrode array recordings from stem cell-derived cardiomyocytes. J.
Pharmacol. Toxicol. Methods 81, 380. doi: 10.1016/j.vascn.2016.02.148
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., et al.
(2014). Chemically defined generation of human cardiomyocytes.Nat. Methods
11, 855–860. doi: 10.1038/nmeth.2999
Clerx, M., Collins, P., de Lange, E., and Volders, P. G. A. (2016). Myokit: a simple
interface to cardiac cellular electrophysiology. Prog. Biophys. Mol. Biol. 120,
100–114. doi: 10.1016/j.pbiomolbio.2015.12.008
Cuellar, A. A., Lloyd, C. M., Nielsen, P. F., Bullivant, D. P., Nickerson, D. P., and
Hunter, P. J. (2003). An overview of CellML 1.1, a biological model description
language. Simulation 79, 740–747. doi: 10.1177/0037549703040939
Del Álamo, J. C., Lemons, D., Serrano, R., Savchenko, A., Cerignoli, F., Bodmer,
R., et al. (2016). High throughput physiological screening of ipsc-derived
cardiomyocytes for drug development. Biochim. Biophys. Acta 1863(7 Pt. B),
1717–1727. doi: 10.1016/j.bbamcr.2016.03.003
Devenyi, R. A., Ortega, F. A., Groenendaal, W., Krogh-Madsen, T., Christini, D. J.,
and Sobie, E. A. (2017). Differential roles of two delayed rectifier potassium
currents in regulation of ventricular action potential duration and arrhythmia
susceptibility. J. Physiol. 595, 2301–2317. doi: 10.1113/JP273191
Du, D. T., Hellen, N., Kane, C., and Terracciano, C. M. (2015). Action potential
morphology of human induced pluripotent stem cell-derived cardiomyocytes
does not predict cardiac chamber specificity and is dependent on cell density.
Biophys. J. 108, 1–4. doi: 10.1016/j.bpj.2014.11.008
Ebert, A. D., Liang, P., and Wu, J. C. (2012). Induced pluripotent stem cells as a
disease modeling and drug screening platform. J. Cardiovasc. Pharmacol. 60,
408–416. doi: 10.1097/FJC.0b013e318247f642
Egashira, T., Yuasa, S., Suzuki, T., Aizawa, Y., Yamakawa, H., Matsuhashi, T., et al.
(2012). Disease characterization using lqts-specific induced pluripotent stem
cells. Cardiovasc. Res. 95, 419–429. doi: 10.1093/cvr/cvs206
Elkins, R. C., Davies, M. R., Brough, S. J., Gavaghan, D. J., Cui, Y., Abi-Gerges,
N., et al. (2013). Variability in high-throughput ion-channel screening data and
consequences for cardiac safety assessment. J. Pharmacol. Toxicol Methods 68,
112–122. doi: 10.1016/j.vascn.2013.04.007
Fatima, A., Xu, G., Shao, K., Papadopoulos, S., Lehmann, M., Arnáiz-Cot, J. J.,
et al. (2011). In vitro modeling of ryanodine receptor 2 dysfunction using
human induced pluripotent stem cells. Cell Physiol. Biochem. 28, 579–592.
doi: 10.1159/000335753
Fink, M., and Noble, D. (2009). Markov models for ion channels : versatility versus
identifiability and speed. Philos. Transa. Series A, Math. Phys. Eng. Sci. 367,
2161–2179. doi: 10.1098/rsta.2008.0301
Friedrichs, G. S., Patmore, L., and Bass, A. (2005). Non-clinical evaluation
of ventricular repolarization (ich s7b): results of an interim survey of
international pharmaceutical companies. J. Pharmacol. Toxicol. Methods 52,
6–11. doi: 10.1016/j.vascn.2005.05.001
Giorgi, M. A., Bolaños, R., Gonzalez, C. D., and Di Girolamo, G. (2010). Qt
interval prolongation: preclinical and clinical testing arrhythmogenesis
in drugs and regulatory implications. Curr. Drug. Saf. 5, 54–57.
doi: 10.2174/157488610789869148
Hansen, N. (2006). “The CMA evolution strategy: a comparing review,” in Towards
a New Evolutionary Computation: Advances on Estimation of Distribution
Algorithms, vol. 192, eds J. A. Lozano, P. Larrañaga, I. Inza, and E. Bengoetxea
(Berlin; Heidelberg: Springer), 75–102. doi: 10.1007/3-540-32494-1_4
Hill, A. V. (1910). The possible effects of the aggregation of the molecules of
haemoglobin on its dissociation curves. J. Physiol. 40, 4–7.
Hindmarsh, A. C., Brown, P. N., Grant, K. E., Lee, S. L., Serban, R., Shumaker,
D. E., et al. (2005). SUNDIALS: suite of nonlinear and differential/algebraic
equation solvers. ACM Trans. Math. Soft. 31, 363–396. doi: 10.1145/1089014.
1089020
Holm, S. (2008). Time to reconsider stem cell ethics–the importance of induced
pluripotent cells. J. Med. Ethics 34, 63–64. doi: 10.1136/jme.2007.023903
Houser, S. R., Margulies, K. B., Murphy, A. M., Spinale, F. G., Francis, G. S.,
Prabhu, S. D., et al. (2012). Animal models of heart failure: a scientific
statement from the american heart association. Circ. Res. 111, 131–150.
doi: 10.1161/RES.0b013e3182582523
Hwang, H. S., Kryshtal, D. O., Feaster, T. K., Sánchez-Freire, V., Zhang, J.,
Kamp, T. J., et al. (2015). Comparable calcium handling of human ipsc-derived
cardiomyocytes generated by multiple laboratories. J. Mol. Cell. Cardiol. 85,
79–88. doi: 10.1016/j.yjmcc.2015.05.003
Itzhaki, I., Maizels, L., Huber, I., Gepstein, A., Arbel, G., Caspi, O., et al. (2012).
Modeling of catecholaminergic polymorphic ventricular tachycardia with
patient-specific human-induced pluripotent stem cells. J. Am. Coll. Cardiol. 60,
990–1000. doi: 10.1016/j.jacc.2012.02.066
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., et al.
(2011). Modelling the long qt syndrome with induced pluripotent stem cells.
Nature 471, 225–229. doi: 10.1038/nature09747
Johnstone, R. H., Bardenet, R., Gavaghan, D. J., and Mirams, G. R. (2017).
Hierarchical Bayesian inference for ion channel screening dose-response data.
Wellcome Open Res. 1:6. doi: 10.12688/wellcomeopenres.9945.2
Johnstone, R. H., Chang, E. T. Y., Bardenet, R., de Boer, T. P., Gavaghan, D. J.,
Pathmanathan, P., et al. (2016). Uncertainty and variability in models of the
Frontiers in Physiology | www.frontiersin.org 11 December 2017 | Volume 8 | Article 986
Lei et al. Tailoring Models to iPSC-CM Lines
cardiac action potential: can we build trustworthy models? J. Mol. Cell Cardiol.
96, 49–62. doi: 10.1016/j.yjmcc.2015.11.018
Jones, E., Oliphant, T., and Peterson, P. (2001). SciPy: Open Source Scientific Tools
for Python. Available online at: https://www.scipy.org/citing.html (Accessed on
August 17, 2017).
Jost, N., Virág, L., Bitay, M., Takács, J., Lengyel, C., Biliczki, P., et al.
(2005). Restricting excessive cardiac action potential and qt prolongation.
Circulation 112, 1392–1399. doi: 10.1161/CIRCULATIONAHA.105.
550111
Jung, C. B., Moretti, A., Mederos y Schnitzler, M., Iop, L., Storch, U., Bellin, M., et
al. (2012). Dantrolene rescues arrhythmogenic ryr2 defect in a patient-specific
stem cell model of catecholaminergic polymorphic ventricular tachycardia.
EMBOMol. Med. 4, 180–191. doi: 10.1002/emmm.201100194
Karakikes, I., Ameen, M., Termglinchan, V., and Wu, J. C. (2015). Human
induced pluripotent stem cell-derived cardiomyocytes: insights into
molecular, cellular, and functional phenotypes. Circ. Res. 117, 80–88.
doi: 10.1161/CIRCRESAHA.117.305365
Kattman, S. J., Witty, A. D., Gagliardi, M., Dubois, N. C., Niapour, M.,
Hotta, A., et al. (2011). Stage-specific optimization of activin/nodal and
bmp signaling promotes cardiac differentiation of mouse and human
pluripotent stem cell lines. Cell Stem Cell 8, 228–240. doi: 10.1016/j.stem.2010.
12.008
Keung, W., Boheler, K. R., and Li, R. A. (2014). Developmental cues for the
maturation of metabolic, electrophysiological and calcium handling properties
of human pluripotent stem cell-derived cardiomyocytes. Stem Cell Res. Ther.
5:17. doi: 10.1186/scrt406
Knollmann, B. C. (2013). Induced pluripotent stem cell-derived cardiomyocytes:
boutique science or valuable arrhythmia model? Circ. Res. 112, 969–976.
discussion: 976. doi: 10.1161/CIRCRESAHA.112.300567
Kramer, J., Obejero-Paz, C. A., Myatt, G., Kuryshev, Y. A., Bruening-Wright,
A., Verducci, J. S., et al. (2013). Mice models: superior to the herg model in
predicting torsade de pointes. Sci. Rep. 3:2100. doi: 10.1038/srep02100
Kujala, K., Paavola, J., Lahti, A., Larsson, K., Pekkanen-Mattila, M., Viitasalo,
M., et al. (2012). Cell model of catecholaminergic polymorphic ventricular
tachycardia reveals early and delayed afterdepolarizations. PLoS ONE 7:e44660.
doi: 10.1371/journal.pone.0044660
Lei, C. L., Wang, K., Gissinger, E., Flint, N., Chabria, M., Badi, L., et al. (2017).
“Tailoring an in silico model to the electrophysiology of individual iPSC-
derived caradiomyocyte lines: one size fits all?,” in Annual Meeting of the Safety
Pharmacology Society (Berlin).
Lian, X., Zhang, J., Azarin, S. M., Zhu, K., Hazeltine, L. B., Bao, X., et al. (2013).
Directed cardiomyocyte differentiation from human pluripotent stem cells
by modulating wnt/β-catenin signaling under fully defined conditions. Nat.
Protoc. 8, 162–175. doi: 10.1038/nprot.2012.150
Liang, P., Lan, F., Lee, A. S., Gong, T., Sanchez-Freire, V., Wang, Y., et al. (2013).
Drug screening using a library of human induced pluripotent stem cell-
derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Circulation 127, 1677–1691. doi: 10.1161/CIRCULATIONAHA.113.
001883
Lieu, D. K., Liu, J., Siu, C. W., McNerney, G. P., Tse, H. F., Abu-Khalil, A., et al.
(2009). Absence of transverse tubules contributes to non-uniform ca(2+)
wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes.
Stem Cells Dev. 18, 1493–1500. doi: 10.1089/scd.2009.0052
Lindgren, S., Bass, A. S., Briscoe, R., Bruse, K., Friedrichs, G. S., Kallman,
M. J., et al. (2008). Benchmarking safety pharmacology regulatory
packages and best practice. J. Pharmacol. Toxicol. Methods 58, 99–109.
doi: 10.1016/j.vascn.2008.07.001
López-Redondo, F., Kurokawa, J., Nomura, F., Kaneko, T., Hamada, T.,
Furukawa, T., et al. (2016). A distribution analysis of action potential
parameters obtained from patch-clamped human stem cell-derived
cardiomyocytes. J. Pharmacol. Sci. 131, 141–145. doi: 10.1016/j.jphs.2016.
04.015
Ma, D., Wei, H., Lu, J., Ho, S., Zhang, G., Sun, X., et al. (2013). Generation
of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a
cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur. Heart
J. 34, 1122–1133. doi: 10.1093/eurheartj/ehs226
Ma, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kamp, T. J.,
et al. (2011). High purity human-induced pluripotent stem cell-derived
cardiomyocytes: electrophysiological properties of action potentials and
ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006–H2017.
doi: 10.1152/ajpheart.00694.2011
Mathur, A., Loskill, P., Shao, K., Huebsch, N., Hong, S., Marcus, S. G., et al. (2015).
Human ipsc-based cardiac microphysiological system for drug screening
applications. Sci. Rep. 5:8883. doi: 10.1038/srep08883
Milani-Nejad, N., and Janssen, P. M. (2014). Small and large animal models in
cardiac contraction research: advantages and disadvantages. Pharmacol. Ther.
141, 235–249. doi: 10.1016/j.pharmthera.2013.10.007
Mirams, G. R., Cui, Y., Sher, A., Fink, M., Cooper, J., Heath, B. M., et al.
(2011). Simulation of multiple ion channel block provides improved early
prediction of compounds’ clinical torsadogenic risk. Cardiovasc. Res. 91, 53–61.
doi: 10.1093/cvr/cvr044
Mirams, G. R., Pathmanathan, P., Gray, R. A., Challenor, P., and Clayton,
R. H. (2016). White paper: uncertainty and variability in computational
and mathematical models of cardiac physiology. J. Physiol. 594, 6833–6847.
doi: 10.1113/JP271671
Moran, A. E., Forouzanfar, M. H., Roth, G. A., Mensah, G. A., Ezzati, M.,
Murray, C. J., et al. (2014). Temporal trends in ischemic heart disease
mortality in 21 world regions, 1980 to 2010: the global burden of disease 2010
study. Circulation 129, 1483–1492. doi: 10.1161/CIRCULATIONAHA.113.
004042
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., et al.
(2010). Patient-specific induced pluripotent stem-cell models for long-qt
syndrome. N. Engl. J. Med. 363, 1397–1409. doi: 10.1056/NEJMoa0908679
Obejero-Paz, C. A., Bruening-Wright, A., Kramer, J., Hawryluk, P., Tatalovic, M.,
Dittrich, H. C., et al. (2015). Quantitative profiling of the effects of vanoxerine
on human cardiac ion channels and its application to cardiac risk. Sci. Rep.
5:17623. doi: 10.1038/srep17623
Ogden, D., and Stanfield, P. (1994). Patch Clamp Techniques for Single Channel and
Whole-Cell Recording, 2nd Edn. Cambridge: The Company of Biologists Ltd.
O’Hara, T., Virág, L., Varró, A., and Rudy, Y. (2011). Simulation of
the undiseased human cardiac ventricular action potential: model
formulation and experimental validation. PLoS Comput. Biol. 7:e1002061.
doi: 10.1371/journal.pcbi.1002061
Okano, H., Nakamura, M., Yoshida, K., Okada, Y., Tsuji, O., Nori, S., et al. (2013).
Steps toward safe cell therapy using induced pluripotent stem cells. Circ. Res.
112, 523–533. doi: 10.1161/CIRCRESAHA.111.256149
Paci, M., Hyttinen, J., Aalto-Setälä, K., and Severi, S. (2013). Computational
models of ventricular- and atrial-like human induced pluripotent
stem cell derived cardiomyocytes. Ann. Biomed. Eng. 41, 2334–2348.
doi: 10.1007/s10439-013-0833-3
Paci, M., Hyttinen, J., Rodriguez, B., and Severi, S. (2015). Human induced
pluripotent stem cell-derived versus adult cardiomyocytes: an in silico
electrophysiological study on effects of ionic current block. Br. J. Pharmacol.
172, 5147–5160. doi: 10.1111/bph.13282
Paci, M., Sartiani, L., Del Lungo, M., Jaconi, M., Mugelli, A., Cerbai, E.,
et al. (2012). Mathematical modelling of the action potential of human
embryonic stem cell derived cardiomyocytes. Biomed. Eng. Online 11:61.
doi: 10.1186/1475-925X-11-61
Po, S., Wang, D., Yang, I. C.-H., Johnson, J. Jr., Nie, L., and Bennett,
P. (1999). Modulation of herg potassium channels by extracellular
magnesium and quinidine. J. Cardiovas. Pharmacol. 33, 181–185.
doi: 10.1097/00005344-199902000-00002
Polak, S., and Fijorek, K. (2012). Inter-individual variability in the pre-
clinical drug cardiotoxic safety assessment–analysis of the age-cardiomyocytes
electric capacitance dependence. J. Cardiovasc. Transl. Res. 5, 321–332.
doi: 10.1007/s12265-012-9357-8
Priori, S. G., Napolitano, C., Di Pasquale, E., and Condorelli, G. (2013).
Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited
arrhythmias. J. Clin. Invest. 123, 84–91. doi: 10.1172/JCI62838
Pugsley, M. K. (2005). Methodology used in safety pharmacology: appraisal of the
state-of-the-art, the regulatory issues and new directions. J. Pharmacol. Toxicol.
Methods 52, 1–5. doi: 10.1016/j.vascn.2005.05.002
Robinton, D. A., and Daley, G. Q. (2012). The promise of induced pluripotent stem
cells in research and therapy. Nature 481, 295–305. doi: 10.1038/nature10761
Rodriguez, M. L., Graham, B. T., Pabon, L. M., Han, S. J., Murry, C. E., and
Sniadecki, N. J. (2014). Measuring the contractile forces of human induced
Frontiers in Physiology | www.frontiersin.org 12 December 2017 | Volume 8 | Article 986
Lei et al. Tailoring Models to iPSC-CM Lines
pluripotent stem cell-derived cardiomyocytes with arrays of microposts. J.
Biomech. Eng. 136:051005. doi: 10.1115/1.4027145
Sager, P. T., Gintant, G., Turner, J. R., Pettit, S., and Stockbridge, N. (2014).
Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report
from the cardiac safety research consortium. Am. Heart J. 167, 292–300.
doi: 10.1016/j.ahj.2013.11.004
Sarkar, A. X., and Sobie, E. A. (2010). Regression analysis for constraining free
parameters in electrophysiological models of cardiac cells. PLoS Comput. Biol.
6:e1000914. doi: 10.1371/journal.pcbi.1000914
Schulz, D. J., Goaillard, J.-M., and Marder, E. (2006). Variable channel expression
in identified single and electrically coupled neurons in different animals. Nat.
Neurosci. 9, 356–362. doi: 10.1038/nn1639
Sedan, O., and Binah, O. (2011). “Excitation-contraction coupling,
functional properties, and autonomic and hormonal regulation in human
embryonic stem cell derived cardiomyocytes,” in Regenerating the Heart.
Stem Cell Biology and Regenerative Medicine (Humana Press), 37–52.
doi: 10.1007/978-1-61779-021-8_4
Shi, Y., Inoue, H., Wu, J. C., and Yamanaka, S. (2017). Induced pluripotent stem
cell technology: a decade of progress. Nat. Rev. Drug. Discov. 16, 115–130.
doi: 10.1038/nrd.2016.245
Silva, J., and Rudy, Y. (2005). Subunit interaction determines iks participation in
cardiac repolarization and repolarization reserve. Circulation 112, 1384–1391.
doi: 10.1161/CIRCULATIONAHA.105.543306
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et
al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell 131, 861–872. doi: 10.1016/j.cell.2007.11.019
Terrenoire, C., Wang, K., Tung, K. W., Chung, W. K., Pass, R. H., Lu, J. T.,
et al. (2013). Induced pluripotent stem cells used to reveal drug actions in a
long qt syndrome family with complex genetics. J. Gen. Physiol. 141, 61–72.
doi: 10.1085/jgp.201210899
van denHeuvel, N. H., van Veen, T. A., Lim, B., and Jonsson, M. K. (2014). Lessons
from the heart: mirroring electrophysiological characteristics during cardiac
development to in vitro differentiation of stem cell derived cardiomyocytes. J.
Mol. Cell Cardiol. 67, 12–25. doi: 10.1016/j.yjmcc.2013.12.011
Wang, K., Lee, P., Mirams, G. R., Sarathchandra, P., Borg, T. K., Gavaghan,
D. J., et al. (2015). Cardiac tissue slices: preparation, handling, and successful
optical mapping. Am. J. Physiol. Heart Circ. Physiol. 308, H1112–H1125.
doi: 10.1152/ajpheart.00556.2014
Weiss, J. N. (1997). The hill equation revisited: uses and misuses. FASEB J. 11,
835–841.
Yazawa, M., Hsueh, B., Jia, X., Pasca, A. M., Bernstein, J. A., Hallmayer, J.,
et al. (2011). Using induced pluripotent stem cells to investigate cardiac
phenotypes in timothy syndrome. Nature 471, 230–234. doi: 10.1038/nature
09855
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane,
J. L., Tian, S., et al. (2007). Induced pluripotent stem cell lines derived
from human somatic cells. Science 318, 1917–1920. doi: 10.1126/science.11
51526
Yu, T., Lloyd, C. M., Nickerson, D. P., Cooling, M. T., Miller, A. K., Garny, A.,
et al. (2011). The Physiome model repository 2. Bioinformatics 27, 743–744.
doi: 10.1093/bioinformatics/btq723
Conflict of Interest Statement: LP and KW were employed by company
F. Hoffmann—La Roche. MH-V, VZ, AA, and GS were employed by Clyde
Biosciences.
The reviewer DK and handling Editor declared their shared affiliation, and
the handling Editor states that the process met the standards of a fair and objective
review.
The other authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2017 Lei, Wang, Clerx, Johnstone, Hortigon-Vinagre, Zamora, Allan,
Smith, Gavaghan, Mirams and Polonchuk. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Physiology | www.frontiersin.org 13 December 2017 | Volume 8 | Article 986
